Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 164

1.

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, Garrison L Jr, Donnell D.

Value Health. 2019 Feb;22(2):194-202. doi: 10.1016/j.jval.2018.09.001. Epub 2018 Nov 2.

PMID:
30711064
2.

Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Hatleberg CI, Ryom L, d'Arminio Monforte A, Fontas E, Reiss P, Kirk O, El-Sadr W, Phillips A, de Wit S, Dabis F, Weber R, Law M, Lundgren JD, Sabin C; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

HIV Med. 2018 Oct;19(9):605-618. doi: 10.1111/hiv.12639. Epub 2018 Jul 18.

PMID:
30019813
3.

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):650-657. doi: 10.1093/cid/ciy508.

PMID:
29912335
4.

Associations between serum albumin and serious non-AIDS events among people living with HIV.

Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, Weber R, Pradier C, De Wit S, Law M, d'Arminio Monforte A, Lundgren J, Mocroft A, Phillips AN, Sabin CA; D:A:D Study Group.

AIDS. 2018 Aug 24;32(13):1837-1848. doi: 10.1097/QAD.0000000000001900.

5.

Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis.

Achhra AC, Sabin C, Ryom L, Hatleberg C, Antonella d ľAminio M, de Wit S, Phillips A, Pradier C, Weber R, Reiss P, El-Sadr W, Bonnet F, Mocroft A, Lundgren J, Law MG; D:A:D Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):579-588. doi: 10.1097/QAI.0000000000001722.

PMID:
29771788
6.

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.

Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, Phillips A, Weber R, Fontas E, d' Arminio Monforte A, De Wit S, Dabis F, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group.

Lancet HIV. 2018 Jun;5(6):e291-e300. doi: 10.1016/S2352-3018(18)30043-2. Epub 2018 May 3.

PMID:
29731407
7.

Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions.

Sayed S, Cherniak W, Lawler M, Tan SY, El Sadr W, Wolf N, Silkensen S, Brand N, Looi LM, Pai SA, Wilson ML, Milner D, Flanigan J, Fleming KA.

Lancet. 2018 May 12;391(10133):1939-1952. doi: 10.1016/S0140-6736(18)30459-8. Epub 2018 Mar 15. Review.

PMID:
29550027
8.

A pragmatic approach to monitor and evaluate implementation and impact of differentiated ART delivery for global and national stakeholders.

Ehrenkranz PD, Calleja JM, El-Sadr W, Fakoya AO, Ford N, Grimsrud A, Harris KL, Jed SL, Low-Beer D, Patel SV, Rabkin M, Reidy WJ, Reinisch A, Siberry GK, Tally LA, Zulu I, Zaidi I.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25080.

9.

The Global HIV Epidemic: What Will It Take to Get to the Finish Line?

Katz IT, Ehrenkranz P, El-Sadr W.

JAMA. 2018 Mar 20;319(11):1094-1095. doi: 10.1001/jama.2018.2093. No abstract available.

PMID:
29509836
10.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

11.

"Testing, Testing": Multiple HIV-Positive Tests among Patients Initiating Antiretroviral Therapy in Ethiopia.

Kulkarni S, Tymejczyk O, Gadisa T, Lahuerta M, Remien RH, Melaku Z, El-Sadr W, Elul B, Nash D, Hoffman S.

J Int Assoc Provid AIDS Care. 2017 Nov/Dec;16(6):546-554. doi: 10.1177/2325957417737840. Epub 2017 Nov 9.

PMID:
29117777
12.

Abacavir use and risk of recurrent myocardial infarction.

Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.

AIDS. 2018 Jan 2;32(1):79-88. doi: 10.1097/QAD.0000000000001666.

PMID:
29028664
13.

Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa.

Bock P, Phiri C, Piwowar-Manning E, Kosloff B, Mandla N, Young A, James A, Schaap A, Scheepers M, Donnell D, Griffith S, El-Sadr W, Shanaube K, Beyers N, Hayes R, Fidler S, Ayles H; HPTN 071 (PopART) Study Team.

J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21780. doi: 10.7448/IAS.20.7.21780.

14.

Willingness to use short-term oral pre-exposure prophylaxis (PrEP) by migrant miners and female partners of migrant miners in Mozambique.

Falcao J, Ahoua L, Zerbe A, di Mattei P, Baggaley R, Chivurre V, Mulondo P, Ramiro I, Dalal S, Morales F, O'Reilly K, El-Sadr W.

Cult Health Sex. 2017 Dec;19(12):1389-1403. doi: 10.1080/13691058.2017.1316424. Epub 2017 May 4.

PMID:
28468533
15.

A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.

Hayes R, Floyd S, Schaap A, Shanaube K, Bock P, Sabapathy K, Griffith S, Donnell D, Piwowar-Manning E, El-Sadr W, Beyers N, Ayles H, Fidler S; HPTN 071 (PopART) Study Team.

PLoS Med. 2017 May 2;14(5):e1002292. doi: 10.1371/journal.pmed.1002292. eCollection 2017 May.

16.
17.

Factors associated with initiation of antiretroviral therapy in the advanced stages of HIV infection in six Ethiopian HIV clinics, 2012 to 2013.

Nash D, Tymejczyk O, Gadisa T, Kulkarni SG, Hoffman S, Yigzaw M, Elul B, Remien RH, Lahuerta M, Daba S, El Sadr W, Melaku Z.

J Int AIDS Soc. 2016 Apr 22;19(1):20637. doi: 10.7448/IAS.19.1.20637. eCollection 2016.

18.

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren JD; D:A:D Study Group.

BMC Med. 2016 Mar 31;14:61. doi: 10.1186/s12916-016-0588-4.

19.

Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals.

Hatleberg CI, Ryom L, El-Sadr W, Smith C, Weber R, Reiss P, Fontas E, Dabis F, Law M, Monforte Ad, De Wit S, Mocroft A, Phillips A, Lundgren JD, Sabin C; D:A:D Study Group.

AIDS. 2016 Jun 19;30(10):1583-96. doi: 10.1097/QAD.0000000000001076.

20.

Costs of Expanded Rapid HIV Testing in Four Emergency Departments.

Schackman BR, Eggman AA, Leff JA, Braunlin M, Felsen UR, Fitzpatrick L, Telzak EE, El-Sadr W, Branson BM.

Public Health Rep. 2016 Jan-Feb;131 Suppl 1:71-81.

Supplemental Content

Loading ...
Support Center